Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241093 | A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 18 | Tarapeutics Science Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 |
| clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05452668 | Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients | unknown | N/A | 51 | Children's Cancer Hospital Egypt 57357OTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05501899 | Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 20 | Children's Hospital of Orange CountyOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05605379 | CML Pediatric ITK Response According to Molecular Identification at Diagnosis(CML Piramid) | unknown | — | 88 | University Hospital, BordeauxOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05873322 | Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma | unknown | — | 100 | Aarhus University HospitalOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06392581 | Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients(ALL-IFI) | unknown | — | 150 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00899223 | Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes | unknown | — | 1,500 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05190653 | Early Integration of Palliative and Supportive Care in Cellular Therapy(PALS_CT) | unknown | N/A | 152 | Alberta Health Services, CalgaryOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06427330 | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | unknown | Phase 2 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06263387 | Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine(VENAZA) | unknown | — | 230 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06512272 | Video-recOrded hospItal dischaRge (VOIR)(VOIR) | unknown | N/A | 60 | Anglia Ruskin UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06512610 | ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML | unknown | — | 100 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06058858 | Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis(CMV CAR-T) | unknown | — | 250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06461091 | the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia(TMI) | unknown | — | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT03450512 | Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy(DECLAM) | unknown | — | 170 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06489184 | The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China | unknown | — | 490 | Peking University People's HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06482281 | COVID-19 and Childhood Cancer | unknown | — | 100,000 | Karolinska InstitutetOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06486350 | IL-6: A Marker for AML Chemo Sensitivity | unknown | — | 72 | Fujian Medical University Union HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT01346020 | Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | unknown | — | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy(CART19-BE-02) | unknown | Phase 2 | 50 | Sara V. LatorreOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06469047 | Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia(RBSNAAMCL) | unknown | — | 80 | Second Hospital of Shanxi Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05371392 | Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia | unknown | — | 80 | Sohag UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06460766 | Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire | unknown | — | 70 | Istanbul University - CerrahpasaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05304156 | Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"(DYNHAEMICS) | unknown | — | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT01305499 | A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 52 | Hetty CarrawayOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03275493 | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 40 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT05241106 | A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 15 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06412692 | Motivational Interviewing in Adolescents With Epilepsy | unknown | N/A | 72 | Izmir Katip Celebi UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05832320 | Optimum Induction Therapy of Low-risk APL | unknown | N/A | 74 | Peking University People's HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT05635266 | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | unknown | — | 20,000 | Sanguine BiosciencesINDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT03466944 | PUMA (Paediatric Osseous Marrow Assessment)(PUMA) | unknown | — | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06393335 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 36 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06379282 | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia(HIT-CLL) | unknown | N/A | 132 | University of SurreyOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06078306 | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06326268 | Interest of Light Therapy in Hematology - The PHOTO-TREAT Study(PHOTO-TREAT) | unknown | N/A | 30 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06367673 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03682029 | Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies(EVITA) | unknown | N/A | 109 | Rigshospitalet, DenmarkOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT06025682 | Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO(INO-FIRST) | unknown | — | 158 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04460950 | Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms | unknown | — | 237 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06084923 | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | unknown | — | 73 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT03481868 | EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors(EPIK) | unknown | N/A | 160 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06353698 | Fasting Mimicking Diet With Chemotherapy in Patients With Leukemia | unknown | N/A | 40 | National Nutrition and Food Technology InstituteOTHER | 1 | Apr 9, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 10, 2025source: clinicaltrials